{"symbol": "ABBV", "publishedDate": "2021-07-23 12:37:00", "publisher": "PRNewsWire", "title": "DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients", "image": "https://images.financialmodelingprep.com/news/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-20210723.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., July 23, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.", "url": "https://www.prnewswire.com/news-releases/dalvance-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin-structure-infections-in-pediatric-patients-301340347.html", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-23T12:37:00-04:00", "date_et": "2021-07-23"}
{"symbol": "ABBV", "publishedDate": "2021-07-24 06:04:00", "publisher": "The Motley Fool", "title": "3 Value Stocks to Buy for the Second Half of 2021", "image": "https://images.financialmodelingprep.com/news/3-value-stocks-to-buy-for-the-second-half-20210724.jpg", "site": "fool.com", "text": "These stocks are cheap, but their underlying businesses are solid.", "url": "https://www.fool.com/investing/2021/07/24/3-value-stocks-to-buy-for-the-second-half-of-2021/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-24T06:04:00-04:00", "date_et": "2021-07-24"}
{"symbol": "ABBV", "publishedDate": "2021-07-25 05:55:00", "publisher": "The Motley Fool", "title": "3 Dividend Stocks to Buy Hand Over Fist If the Market Crashes", "image": "https://images.financialmodelingprep.com/news/3-dividend-stocks-to-buy-hand-over-fist-if-the-20210725.jpg", "site": "fool.com", "text": "You'll be able to lock in fantastic dividend yields if you do.", "url": "https://www.fool.com/investing/2021/07/25/3-dividend-stocks-to-buy-hand-over-fist-if-the-mar/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-25T05:55:00-04:00", "date_et": "2021-07-25"}
{"symbol": "ABBV", "publishedDate": "2021-07-25 11:31:00", "publisher": "PRNewsWire", "title": "New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition", "image": "https://images.financialmodelingprep.com/news/new-data-presented-on-the-safety-and-efficacy-of-20210725.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., July 25, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.", "url": "https://www.prnewswire.com/news-releases/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia-a-common-and-progressive-eye-condition-301339937.html", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-25T11:31:00-04:00", "date_et": "2021-07-25"}
{"symbol": "ABBV", "publishedDate": "2021-07-26 19:09:35", "publisher": "Zacks Investment Research", "title": "AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-stock-sinks-as-market-gains-what-you-20210726.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) closed at $117.79 in the latest trading session, marking a -0.34% move from the prior day.", "url": "https://www.zacks.com/stock/news/1767932/abbvie-abbv-stock-sinks-as-market-gains-what-you-should-know", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-26T19:09:35-04:00", "date_et": "2021-07-26"}
{"symbol": "ABBV", "publishedDate": "2021-07-27 07:36:52", "publisher": "24/7 Wall Street", "title": "S&P 500 Dividend Yield Lowest in 20 Years: 5 Blue Chips to Buy Now With Huge Dividends", "image": "https://images.financialmodelingprep.com/news/sp-500-dividend-yield-lowest-in-20-years-5-20210727.jpg", "site": "247wallst.com", "text": "Time and time again, the Wall Street pundits say interest rates are going higher, and time and time again they plunge lower.", "url": "https://247wallst.com/investing/2021/07/27/sp-500-dividend-yield-lowest-in-20-years-5-blue-chips-to-buy-now-with-huge-dividends/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-27T07:36:52-04:00", "date_et": "2021-07-27"}
{"symbol": "ABBV", "publishedDate": "2021-07-27 08:30:00", "publisher": "PRNewsWire", "title": "AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases", "image": "https://images.financialmodelingprep.com/news/abbvie-and-calico-announce-second-extension-of-collaboration-focused-20210727.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif.", "url": "https://www.prnewswire.com/news-releases/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age-related-diseases-301341606.html", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-27T08:30:00-04:00", "date_et": "2021-07-27"}
{"symbol": "ABBV", "publishedDate": "2021-07-27 09:22:29", "publisher": "Marijuana Stocks", "title": "AbbVie Inc. (ABBV) and Calico Announce Second Extension of Collaboration", "image": "https://images.financialmodelingprep.com/news/abbvie-inc-abbv-and-calico-announce-second-extension-of-20210727.jpg", "site": "marijuanastocks.com", "text": "AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and… The post AbbVie Inc. (ABBV) and Calico Announce Second Extension of Collaboration appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.", "url": "https://marijuanastocks.com/abbv-and-calico-announce-second-extension-of-collaboration/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-27T09:22:29-04:00", "date_et": "2021-07-27"}
{"symbol": "ABBV", "publishedDate": "2021-07-27 10:48:55", "publisher": "Benzinga", "title": "AbbVie, Alphabet-Founded Calico Extends Collaboration Focused on Aging, Age-Related Diseases", "image": "https://images.financialmodelingprep.com/news/abbvie-alphabetfounded-calico-extends-collaboration-focused-on-aging-agerelated-20210727.jpg", "site": "benzinga.com", "text": "AbbVie Inc (NYSE: ABBV) and Calico Life Sciences have collaborated to discover and develop new therapies for patients with age-related diseases, including neurodegeneration and cancer.  It is the second extension of the collaboration initially established in 2014.", "url": "https://www.benzinga.com/general/biotech/21/07/22173909/abbvie-alphabet-founded-calico-extends-collaboration-focused-on-aging-age-related-diseases", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-27T10:48:55-04:00", "date_et": "2021-07-27"}
{"symbol": "ABBV", "publishedDate": "2021-07-27 17:35:21", "publisher": "Zacks Investment Research", "title": "2 Blue Chip Stocks to Buy Before Earnings and Hold for Years", "image": "https://images.financialmodelingprep.com/news/2-blue-chip-stocks-to-buy-before-earnings-and-20210727.jpg", "site": "zacks.com", "text": "Let's explore two blue chip stocks that investors might want to consider buying as they report Q2 earnings.", "url": "https://www.zacks.com/stock/news/1768874/2-blue-chip-stocks-to-buy-before-earnings-and-hold-for-years", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-27T17:35:21-04:00", "date_et": "2021-07-27"}
{"symbol": "ABBV", "publishedDate": "2021-07-29 08:30:00", "publisher": "PRNewsWire", "title": "FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity", "image": "https://images.financialmodelingprep.com/news/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-20210729.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX® to include eight new muscles for the treatment of upper limb spasticity in adults.", "url": "https://www.prnewswire.com/news-releases/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity-301343906.html", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-29T08:30:00-04:00", "date_et": "2021-07-29"}
{"symbol": "ABBV", "publishedDate": "2021-07-29 08:31:00", "publisher": "The Motley Fool", "title": "Market Crash 2.0: Where to Invest $1,000", "image": "https://images.financialmodelingprep.com/news/market-crash-20-where-to-invest-1000-20210729.jpg", "site": "fool.com", "text": "These two companies will be excellent buys in the event of another coronavirus-fueled market crash.", "url": "https://www.fool.com/investing/2021/07/29/market-crash-20-where-to-invest-1000/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-29T08:31:00-04:00", "date_et": "2021-07-29"}
{"symbol": "ABBV", "publishedDate": "2021-07-29 09:40:00", "publisher": "The Motley Fool", "title": "This Biotech Stock Is Too Cheap to Ignore", "image": "https://images.financialmodelingprep.com/news/this-biotech-stock-is-too-cheap-to-ignore-20210729.png", "site": "fool.com", "text": "Wall Street's short attention span has created an attractive entry point in this once-loved biotech.", "url": "https://www.fool.com/investing/2021/07/29/this-biotech-stock-is-too-cheap-to-ignore/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-29T09:40:00-04:00", "date_et": "2021-07-29"}
{"symbol": "ABBV", "publishedDate": "2021-07-29 10:35:12", "publisher": "The Motley Fool", "title": "How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market", "image": "https://images.financialmodelingprep.com/news/how-abbvie-could-make-an-entry-into-this-rapidly-growing-20210729.jpg", "site": "fool.com", "text": "Venclexta's potential indication for the treatment of myelodysplastic syndrome could mean billions for AbbVie this decade.", "url": "https://www.fool.com/investing/2021/07/29/how-abbvie-could-make-an-entry-into-this-rapidly-g/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-29T10:35:12-04:00", "date_et": "2021-07-29"}
{"symbol": "ABBV", "publishedDate": "2021-07-29 23:28:57", "publisher": "Seeking Alpha", "title": "5 Blue-Chip Bargains That Create The World's Safest 6% Yielding Retirement Portfolio", "image": "https://images.financialmodelingprep.com/news/5-bluechip-bargains-that-create-the-worlds-safest-6-20210729.jpg", "site": "seekingalpha.com", "text": "5 Blue-Chip Bargains That Create The World's Safest 6% Yielding Retirement Portfolio", "url": "https://seekingalpha.com/article/4442864-5-blue-chip-bargains-that-create-the-worlds-safest-6-percent-yielding-retirement-portfolio", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-29T23:28:57-04:00", "date_et": "2021-07-29"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 07:44:00", "publisher": "PRNewsWire", "title": "AbbVie Reports Second-Quarter 2021 Financial Results", "image": "https://images.financialmodelingprep.com/news/abbvie-reports-secondquarter-2021-financial-results-20210730.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., July 30, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2021.", "url": "https://www.prnewswire.com/news-releases/abbvie-reports-second-quarter-2021-financial-results-301345065.html", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T07:44:00-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 07:49:00", "publisher": "Reuters", "title": "AbbVie raises annual profit forecast as Botox demand rebounds", "image": "https://images.financialmodelingprep.com/news/abbvie-raises-annual-profit-forecast-as-botox-demand-rebounds-20210730.jpg", "site": "reuters.com", "text": "Drugmaker AbbVie Inc raised its full-year adjusted profit forecast on Friday, as demand soared for its Botox anti-wrinkle injection in the second quarter following the easing of COVID-19 restrictions.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-botox-demand-rebounds-2021-07-30/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T07:49:00-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 07:53:17", "publisher": "Benzinga", "title": "Recap: AbbVie Q2 Earnings", "image": "https://images.financialmodelingprep.com/news/recap-abbvie-q2-earnings-20210730.jpg", "site": "benzinga.com", "text": "Shares of AbbVie (NYSE:ABBV) decreased 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 32.91% over the past year to $3.11, which beat the estimate of $3.09.", "url": "https://www.benzinga.com/news/earnings/21/07/22245350/recap-abbvie-q2-earnings", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T07:53:17-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 08:17:52", "publisher": "Market Watch", "title": "AbbVie cites growth of immunology business in the second quarter", "image": "https://images.financialmodelingprep.com/news/abbvie-cites-growth-of-immunology-business-in-the-second-20210730.jpg", "site": "marketwatch.com", "text": "AbbVie Inc. beat expectations for the second quarter of 2021, driven largely by gains in its immunology business. The drug maker had earnings of $766 million, or 42 cents per share, in the second quarter of 2021.", "url": "https://www.marketwatch.com/story/abbvie-cites-growth-of-immunology-business-in-the-second-quarter-2021-07-30", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T08:17:52-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 08:19:55", "publisher": "Benzinga", "title": "AbbVie Q2 Earnings Beats Consensus Slightly; Guides FY21 EPS Below Consensus", "image": "https://images.financialmodelingprep.com/news/abbvie-q2-earnings-beats-consensus-slightly-guides-fy21-eps-below-20210730.jpg", "site": "benzinga.com", "text": "AbbVie Inc (NYSE: ABBV) reports Q2 adjusted EPS of $3.11, marginally beating the consensus of $3.09. Overall sales increased 33.9% Y/Y to $13.9 billion, slightly ahead of the consensus of $13.6 billion.", "url": "https://www.benzinga.com/general/biotech/21/07/22245963/abbvie-q2-earnings-beats-consensus-slightly-guides-fy21-eps-below-consensus", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T08:19:55-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 10:14:16", "publisher": "The Motley Fool", "title": "Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider", "image": "https://images.financialmodelingprep.com/news/have-500-here-are-2-highyielding-healthcare-stocks-to-20210730.jpg", "site": "fool.com", "text": "These two companies offer impressive -- and safe -- yields for investors who like income.", "url": "https://www.fool.com/investing/2021/07/30/have-500-here-are-2-high-yielding-healthcare-stock/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T10:14:16-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 10:39:34", "publisher": "Zacks Investment Research", "title": "AbbVie (ABBV) Q2 Earnings Match Estimates", "image": "https://images.financialmodelingprep.com/news/abbvie-abbv-q2-earnings-match-estimates-20210730.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) delivered earnings and revenue surprises of 0.00% and 1.81%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?", "url": "https://www.zacks.com/stock/news/1771515/abbvie-abbv-q2-earnings-match-estimates", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T10:39:34-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 12:55:25", "publisher": "Zacks Investment Research", "title": "AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised", "image": "https://images.financialmodelingprep.com/news/abbvies-abbv-q2-earnings-in-line-2021-guidance-raised-20210730.jpg", "site": "zacks.com", "text": "AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.", "url": "https://www.zacks.com/stock/news/1771905/abbvie-s-abbv-q2-earnings-in-line-2021-guidance-raised", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T12:55:25-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-07-30 17:52:06", "publisher": "Seeking Alpha", "title": "AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2021 Results - Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/abbvie-inc-abbv-ceo-rick-gonzalez-on-q2-2021-20210730.jpg", "site": "seekingalpha.com", "text": "AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2021 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4443372-abbvie-inc-abbv-ceo-rick-gonzalez-on-q2-2021-results-earnings-call-transcript", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-07-30T17:52:06-04:00", "date_et": "2021-07-30"}
{"symbol": "ABBV", "publishedDate": "2021-08-01 07:01:00", "publisher": "The Motley Fool", "title": "3 Underrated Warren Buffett Stocks That Are Smart Buys Right Now", "image": "https://images.financialmodelingprep.com/news/3-underrated-warren-buffett-stocks-that-are-smart-buys-20210801.jpg", "site": "fool.com", "text": "They're either beaten down, bargains, or both.", "url": "https://www.fool.com/investing/2021/08/01/3-underrated-warren-buffett-stocks-smart-buys-now/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-01T07:01:00-04:00", "date_et": "2021-08-01"}
{"symbol": "ABBV", "publishedDate": "2021-08-01 18:37:21", "publisher": "Seeking Alpha", "title": "Abbvie - Still Undervalued With More Room To Grow", "image": "https://images.financialmodelingprep.com/news/abbvie-still-undervalued-with-more-room-to-grow-20210801.jpg", "site": "seekingalpha.com", "text": "Abbvie - Still Undervalued With More Room To Grow", "url": "https://seekingalpha.com/article/4443882-abbvie-stock-abbv-still-undervalued-with-more-room-to-grow", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-01T18:37:21-04:00", "date_et": "2021-08-01"}
{"symbol": "ABBV", "publishedDate": "2021-08-04 07:35:58", "publisher": "24/7 Wall Street", "title": "4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows", "image": "https://images.financialmodelingprep.com/news/4-big-pharma-dividend-stocks-to-buy-as-yields-20210804.jpg", "site": "247wallst.com", "text": "It has become the proverbial broken record. Every time it seems like yields on government securities will start trending higher, they roll over again.", "url": "https://247wallst.com/healthcare-business/2021/08/04/4-big-pharmaceutical-dividend-stocks-to-buy-as-yields-near-2021-lows/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-04T07:35:58-04:00", "date_et": "2021-08-04"}
{"symbol": "ABBV", "publishedDate": "2021-08-04 08:34:31", "publisher": "Forbes", "title": "Why AbbVie Is A Top 25 Dividend Giant", "image": "https://images.financialmodelingprep.com/news/why-abbvie-is-a-top-25-dividend-giant-20210804.jpg", "site": "forbes.com", "text": "AbbVie has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $22.35B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 4.47% yield", "url": "https://www.forbes.com/sites/dividendchannel/2021/08/04/why-abbvie-is-a-top-25-dividend-giant/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-04T08:34:31-04:00", "date_et": "2021-08-04"}
{"symbol": "ABBV", "publishedDate": "2021-08-04 12:01:00", "publisher": "PRNewsWire", "title": "JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis", "image": "https://images.financialmodelingprep.com/news/jama-dermatology-publishes-data-showing-rinvoq-upadacitinib-achieved-superiority-20210804.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., Aug. 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ® (upadacitinib, 30 mg, once daily) versus DUPIXENT® (dupilumab, 300 mg, every other week) – both as monotherapy treatments – in adults with moderate to severe atopic dermatitis who were candidates for systemic therapy.", "url": "https://www.prnewswire.com/news-releases/jama-dermatology-publishes-data-showing-rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ranked-secondary-endpoints-in-phase-3b-head-to-head-study-in-adults-with-atopic-dermatitis-301348484.html", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-04T12:01:00-04:00", "date_et": "2021-08-04"}
{"symbol": "ABBV", "publishedDate": "2021-08-05 17:17:27", "publisher": "Seeking Alpha", "title": "CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company", "image": "https://images.financialmodelingprep.com/news/collplant-biotechnologies-a-cheap-gamechanging-bioprinting-platform-company-20210805.jpg", "site": "seekingalpha.com", "text": "CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company", "url": "https://seekingalpha.com/article/4445642-collplant-cheap-game-changing-bio-printing-platform-company", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-05T17:17:27-04:00", "date_et": "2021-08-05"}
{"symbol": "ABBV", "publishedDate": "2021-08-07 10:02:00", "publisher": "The Motley Fool", "title": "Here Are the Winners of Cowen's Big Pharma R&D Showdown", "image": "https://images.financialmodelingprep.com/news/here-are-the-winners-of-cowens-big-pharma-rd-20210807.jpg", "site": "fool.com", "text": "The Wall Street firm put big drugmakers' R&D programs through five different tests.", "url": "https://www.fool.com/investing/2021/08/07/here-are-the-winners-of-cowens-big-pharma-rd-penta/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-07T10:02:00-04:00", "date_et": "2021-08-07"}
{"symbol": "ABBV", "publishedDate": "2021-08-08 05:52:00", "publisher": "The Motley Fool", "title": "Here Are the 12 Best Dividend Stocks I Own Right Now", "image": "https://images.financialmodelingprep.com/news/here-are-the-12-best-dividend-stocks-i-own-20210808.jpg", "site": "fool.com", "text": "All of them offer attractive dividends and solid growth prospects, too.", "url": "https://www.fool.com/investing/2021/08/08/here-are-the-12-best-dividend-stocks-i-own-right-n/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-08T05:52:00-04:00", "date_et": "2021-08-08"}
{"symbol": "ABBV", "publishedDate": "2021-08-08 07:24:11", "publisher": "24/7 Wall Street", "title": "5 Top Stocks Analysts Want You To Buy Now", "image": "https://images.financialmodelingprep.com/news/5-top-stocks-analysts-want-you-to-buy-now-20210808.jpg", "site": "247wallst.com", "text": "24/7 Wall St. reviews dozens of analyst research reports each day of the week with a goal of finding new ideas for investors and traders alike.", "url": "https://247wallst.com/investing/2021/08/08/5-top-stocks-analysts-want-you-to-buy-now/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-08T07:24:11-04:00", "date_et": "2021-08-08"}
{"symbol": "ABBV", "publishedDate": "2021-08-08 07:37:30", "publisher": "Seeking Alpha", "title": "AbbVie: Continued Performance", "image": "https://images.financialmodelingprep.com/news/abbvie-continued-performance-20210808.jpg", "site": "seekingalpha.com", "text": "When AbbVie announced the acquisition of Allergan in 2019, I had reservations, but was upbeat as investors reacted with extreme caution. The acquisition of Allergan has been integrated well, as organic growth is solid and the Humira reliance is gradually coming down further.", "url": "https://seekingalpha.com/article/4446747-abbvie-continued-performance", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-08T07:37:30-04:00", "date_et": "2021-08-08"}
{"symbol": "ABBV", "publishedDate": "2021-08-08 07:51:59", "publisher": "Seeking Alpha", "title": "AbbVie: Similar To Equity Bond With 12.5% Yield", "image": "https://images.financialmodelingprep.com/news/abbvie-similar-to-equity-bond-with-125-yield-20210808.jpg", "site": "seekingalpha.com", "text": "This article analyzes AbbVie Inc. under the framework of perpetual growth and Buffett's 10x Pretax Rule. Based on such examination, ABBV presents excellent prospects for offering double-digit return in the long term with a wide margin of safety.", "url": "https://seekingalpha.com/article/4446749-abbvie-similar-to-equity-bond-with-12-5-percent-yield", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-08T07:51:59-04:00", "date_et": "2021-08-08"}
{"symbol": "ABBV", "publishedDate": "2021-08-08 09:35:00", "publisher": "Seeking Alpha", "title": "3 Big Dividends, Paying Monthly, For Your Retirement Basea", "image": "https://images.financialmodelingprep.com/news/3-big-dividends-paying-monthly-for-your-retirement-basea-20210808.jpg", "site": "seekingalpha.com", "text": "A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better.", "url": "https://seekingalpha.com/article/4445467-3-big-dividends-paying-monthly-for-your-retirement-base", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-08T09:35:00-04:00", "date_et": "2021-08-08"}
{"symbol": "ABBV", "publishedDate": "2021-08-08 11:30:59", "publisher": "Seeking Alpha", "title": "3 Reasons We Like AbbVie Today", "image": "https://images.financialmodelingprep.com/news/3-reasons-we-like-abbvie-today-20210808.jpg", "site": "seekingalpha.com", "text": "In an overvalued market - AbbVie offers growing dividends for dividend-seeking investors, and it's still undervalued for value investors seeking value upside. AbbVie generates ample free cash to cover their debt, and they are ready to offset Humira's decline in 2023.", "url": "https://seekingalpha.com/article/4446838-3-reasons-we-like-abbvie-stock-abbv-today", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-08T11:30:59-04:00", "date_et": "2021-08-08"}
{"symbol": "ABBV", "publishedDate": "2021-08-08 21:39:31", "publisher": "Seeking Alpha", "title": "AbbVie: Diversified Strength Tempers The Humira Patent Cliff Ahead", "image": "https://images.financialmodelingprep.com/news/abbvie-diversified-strength-tempers-the-humira-patent-cliff-ahead-20210808.jpg", "site": "seekingalpha.com", "text": "AbbVie's diversified & strong collection of products will temper the 2023 Humira patent cliff that could decline revenues by $9B. The market has factored in incredible risk from Humira by valuing AbbVie at just over 10 times free cash flow.", "url": "https://seekingalpha.com/article/4447020-abbvie-diversified-strength-tempers-the-humira-patent-cliff-ahead", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-08T21:39:31-04:00", "date_et": "2021-08-08"}
{"symbol": "ABBV", "publishedDate": "2021-08-09 04:00:00", "publisher": "Business Wire", "title": "Mission and AbbVie Collaboration in Alzheimer's and Parkinson's Diseases Reaches Next Milestone", "image": "https://images.financialmodelingprep.com/news/mission-and-abbvie-collaboration-in-alzheimers-and-parkinsons-diseases-20210809.jpg", "site": "businesswire.com", "text": "CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics (“Mission”), a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (“AbbVie”)(NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegenerative disease collaboration. In the second major milestone of the Companies' research and preclinical development collaboration, AbbVie has nominated two DUB targets to progress", "url": "https://www.businesswire.com/news/home/20210809005029/en/Mission-and-AbbVie-Collaboration-in-Alzheimer%E2%80%99s-and-Parkinson%E2%80%99s-Diseases-Reaches-Next-Milestone/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-09T04:00:00-04:00", "date_et": "2021-08-09"}
{"symbol": "ABBV", "publishedDate": "2021-08-09 07:07:41", "publisher": "Benzinga", "title": "AbbVie Returns Eye Drug Candidate To Molecular Partners", "image": "https://images.financialmodelingprep.com/news/abbvie-returns-eye-drug-candidate-to-molecular-partners-20210809.jpg", "site": "benzinga.com", "text": "AbbVie Inc (NYSE: ABBV) has terminated its license and collaboration agreement with Molecular Partners AG (NASDAQ: MOLN) for abicipar pegol for neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME).  As such, Molecular Partners will regain the development and commercial rights of abicipar on a worldwide basis.", "url": "https://www.benzinga.com/general/biotech/21/08/22394581/abbvie-returns-eye-drug-candidate-to-molecular-partners", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-09T07:07:41-04:00", "date_et": "2021-08-09"}
{"symbol": "ABBV", "publishedDate": "2021-08-09 08:26:20", "publisher": "Seeking Alpha", "title": "Wall Street Breakfast (Podcast)", "image": "https://images.financialmodelingprep.com/news/wall-street-breakfast-podcast-20210809.jpg", "site": "seekingalpha.com", "text": "Wall Street Breakfast (Podcast)", "url": "https://seekingalpha.com/article/4447130-wall-street-breakfast-podcast", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-09T08:26:20-04:00", "date_et": "2021-08-09"}
{"symbol": "ABBV", "publishedDate": "2021-08-09 08:45:00", "publisher": "PRNewsWire", "title": "SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis", "image": "https://images.financialmodelingprep.com/news/skyrizi-risankizumabrzaa-now-available-in-the-us-as-a-20210809.jpg", "site": "prnewswire.com", "text": "NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that SKYRIZI® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis.", "url": "https://www.prnewswire.com/news-releases/skyrizi-risankizumab-rzaa-now-available-in-the-us-as-a-single-150-mg-injection-for-adults-with-moderate-to-severe-plaque-psoriasis-301350489.html", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-09T08:45:00-04:00", "date_et": "2021-08-09"}
{"symbol": "ABBV", "publishedDate": "2021-08-09 09:00:00", "publisher": "Seeking Alpha", "title": "AbbVie: An Undervalued 4.52% Dividend Machine With A Huge Pipeline Of Possibilities", "image": "https://images.financialmodelingprep.com/news/abbvie-an-undervalued-452-dividend-machine-with-a-huge-20210809.jpg", "site": "seekingalpha.com", "text": "For the past decade, AbbVie has sequentially increased its revenue YoY, driving annual increases in gross profits and billions upon billions in annual profits. AbbVie just came off a record 2020 year for revenue and smashed Q2 generating $13.96 billion of revenue, an increase of 33.9% YoY and raised fiscal 2021 guidance.", "url": "https://seekingalpha.com/article/4446970-abbvie-undervalued-dividend-stock-huge-pipeline-possibilities", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-09T09:00:00-04:00", "date_et": "2021-08-09"}
{"symbol": "ABBV", "publishedDate": "2021-08-09 13:50:29", "publisher": "Benzinga", "title": "AbbVie, Mission Therapeutics Pick Alzheimer's & Parkinson's Targets In Neurodegenerative Disease Collaboration", "image": "https://images.financialmodelingprep.com/news/abbvie-mission-therapeutics-pick-alzheimers-parkinsons-targets-in-neurodegenerative-disease-20210809.jpg", "site": "benzinga.com", "text": "AbbVie Inc (NYSE: ABBV) has advanced its collaboration with privately-held Mission Therapeutics, with the nomination of two DUB targets to take into the next stage of drug discovery. This selection follows supportive data from in vitro and in vivo Alzheimer's and Parkinson's disease models.", "url": "https://www.benzinga.com/general/biotech/21/08/22404180/abbvie-mission-therapeutics-pick-alzheimers-parkinsons-targets-in-neurodegenerative-disease-colla", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-09T13:50:29-04:00", "date_et": "2021-08-09"}
{"symbol": "ABBV", "publishedDate": "2021-08-09 15:48:34", "publisher": "Seeking Alpha", "title": "AbbVie: Strong Earnings Make Bull Case For Reassuringly Undervalued Pharma", "image": "https://images.financialmodelingprep.com/news/abbvie-strong-earnings-make-bull-case-for-reassuringly-undervalued-20210809.jpg", "site": "seekingalpha.com", "text": "AbbVie management has set itself the tough challenge of dealing with the patent expiry of $20bn selling Humira while maintaining top-line revenue growth.", "url": "https://seekingalpha.com/article/4447345-abbvie-strong-earnings-make-bull-case-for-reassuringly-undervalued-pharma", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-09T15:48:34-04:00", "date_et": "2021-08-09"}
{"symbol": "ABBV", "publishedDate": "2021-08-10 06:35:00", "publisher": "The Motley Fool", "title": "3 Key Takeaways From AbbVie's Second-Quarter Earnings", "image": "https://images.financialmodelingprep.com/news/3-key-takeaways-from-abbvies-secondquarter-earnings-20210810.jpg", "site": "fool.com", "text": "The company's future looks increasingly bright.", "url": "https://www.fool.com/investing/2021/08/10/3-key-takeaways-from-abbvies-second-quarter-earnin/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-10T06:35:00-04:00", "date_et": "2021-08-10"}
{"symbol": "ABBV", "publishedDate": "2021-08-13 06:22:00", "publisher": "The Motley Fool", "title": "What Rinvoq's Positive News Means for AbbVie", "image": "https://images.financialmodelingprep.com/news/what-rinvoqs-positive-news-means-for-abbvie-20210813.jpg", "site": "fool.com", "text": "If the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market.", "url": "https://www.fool.com/investing/2021/08/13/what-rinvoqs-positive-news-means-for-abbvie/", "ticker": "ABBV", "event_date": "2021-07-30", "window_start": "2021-07-23", "window_end": "2021-08-13", "publishedDateET": "2021-08-13T06:22:00-04:00", "date_et": "2021-08-13"}
